{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:53:26Z","timestamp":1788386006481,"version":"build-2803163510"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"\n Background:<\/jats:title>\n Elafin is a serine protease inhibitor with anti-inflammatory properties. It is expressed in various epithelial tissues with increased production under inflammatory conditions. Increased tissue elafin expression in Beh\u00e7et's disease (BD) lesions has previously been demonstrated.<\/jats:p>\n <\/jats:sec>\n \n Aims and Objectives:<\/jats:title>\n We hypothesised that serum elafin might be increased in patients with BD and aimed to assess the relationship of serum elafin with disease activity and organ involvement in BD.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n Fifty-four BD patients (29 active, 25 inactive) and 30 healthy controls were included in this single-centre case-control study. Serum elafin was measured using ELISA. Complete blood count, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) tests were also performed.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Serum elafin levels were significantly higher in patients with BD (1.58 \u00b1 0.47 ng\/ml, range: 0.67\u20132.96) compared to controls (1.10 \u00b1 0.28 ng\/ml, range: 0.65\u20131.49) (\n P<\/jats:italic>\n < 0.001). Patients with active BD had higher elafin levels than patients with inactive BD (\n P<\/jats:italic>\n = 0.008). Active arthritis was associated with an increase in elafin (\n P<\/jats:italic>\n = 0.012), while the presence of mucocutaneous symptoms was not. Serum elafin correlated significantly with ESR (\n P<\/jats:italic>\n = 0.001). The ideal cut-off value for the diagnosis of BD was determined as 1.24 ng\/ml with a sensitivity and specificity of 72.2% and 70.0%, respectively.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Serum elafin is significantly increased in patients with BD. It may serve as a marker of disease activity, especially articular involvement.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijd.ijd_913_22","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T02:26:16Z","timestamp":1715739976000},"page":"372-376","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Serum Elafin as a Potential Marker of Disease Activity in Beh\u00e7et's Disease"],"prefix":"10.4103","volume":"68","author":[{"given":"Armagan","family":"Kutlay","sequence":"first","affiliation":[{"name":"From the Department of Dermatology and Venereology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afet Akdag","family":"Kose","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and Venereology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20240829","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3389\/fimmu.2019.00665","article-title":"Immunopathogenesis of Behcet's disease","volume":"10","author":"Tong","year":"2019","journal-title":"Front Immunol"},{"key":"R2-20240829","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1042\/CS20050115","article-title":"SLPI and elafin: One glove, many fingers","volume":"110","author":"Williams","year":"2006","journal-title":"Clin Sci (Lond)"},{"key":"R3-20240829","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1365-2133.2000.03766.x","article-title":"Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: Interleukin-1 beta and tumour necrosis factor-alpha stimulate its secretion in vitro","volume":"143","author":"Tanaka","year":"2000","journal-title":"Br J Dermatol"},{"key":"R4-20240829","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/jdv.13650","article-title":"Deposition of elafin in the involved vascular wall of neutrophil-mediated cutaneous vasculitis","volume":"30","author":"Muto","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R5-20240829","first-page":"1078","article-title":"International Study Group for Beh\u00e7et's Disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"R6-20240829","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et's Disease (ICBD): A collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R7-20240829","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s10238-004-0033-4","article-title":"Behcet's disease","volume":"4","author":"Suzuki Kurokawa","year":"2004","journal-title":"Clin Exp Med"},{"key":"R8-20240829","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1515\/bchm2.1981.362.2.1369","article-title":"An elastase-specific inhibitor from human bronchial mucus. Isolation and characterization","volume":"362","author":"Hochstrasser","year":"1981","journal-title":"Hoppe-Seyler's Z Physiol Chem"},{"key":"R9-20240829","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.biocel.2012.05.007","article-title":"The WAP protein Trappin-2\/Elafin: A handyman in the regulation of inflammatory and immune responses","volume":"44","author":"Verrier","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"R10-20240829","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2133.1990.tb07285.x","article-title":"Skin-derived antileucoproteases (SKALPs): Characterization of two new elastase inhibitors from psoriatic epidermis","volume":"122","author":"Schalkwijk","year":"1990","journal-title":"Br J Dermatol"},{"key":"R11-20240829","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1172\/JCI118926","article-title":"Constitutive and inducible expression of SKALP\/elafin provides anti-elastase defense in human epithelia","volume":"98","author":"Pfundt","year":"1996","journal-title":"J Clin Invest"},{"key":"R12-20240829","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-3083.2009.02337.x","article-title":"Human gammadelta T cells produce the protease inhibitor and antimicrobial peptide elafin","volume":"70","author":"Marischen","year":"2009","journal-title":"Scand J Immunol"},{"key":"R13-20240829","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.imlet.2016.12.001","article-title":"An elevated pro-inflammatory cytokines profile in Behcet's disease: A multiplex analysis","volume":"186","author":"Gholijani","year":"2017","journal-title":"Immunol Lett"},{"key":"R14-20240829","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/BF02505235","article-title":"Expression of SKALP\/elafin during wound healing in human skin","volume":"288","author":"van Bergen","year":"1996","journal-title":"Arch Dermatol Res"},{"key":"R15-20240829","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/jdv.15387","article-title":"A potential contribution of trappin-2 to the development of vasculopathy in systemic sclerosis","volume":"33","author":"Miyagawa","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R16-20240829","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.bcp.2011.11.003","article-title":"Role of the endogenous elastase inhibitor, elafin, in cardiovascular injury: From epithelium to endothelium","volume":"83","author":"Alam","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"R17-20240829","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/ijd.14217","article-title":"Serum elafin as a potential inflammatory marker in psoriasis","volume":"58","author":"Elgharib","year":"2019","journal-title":"Int J Dermatol"},{"key":"R18-20240829","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2466-11-35","article-title":"Sputum and nasal lavage lung-specific biomarkers before and after smoking cessation","volume":"11","author":"Bouloukaki","year":"2011","journal-title":"BMC Pulm Med"},{"key":"R19-20240829","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41927-021-00241-z","article-title":"Predictive value of erythrocyte sedimentation rate and C-reactive protein in Behcet's disease activity and manifestations: A cross-sectional study","volume":"6","author":"Parsaei","year":"2022","journal-title":"BMC Rheumatol"},{"key":"R20-20240829","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1111\/1756-185X.13404","article-title":"Neutrophil-to-lymphocyte ratio, mean platelet volume and platelet-to-lymphocyte ratio in Beh\u00e7et's disease and their correlation with disease activity: A meta-analysis","volume":"21","author":"Lee","year":"2018","journal-title":"Int J Rheum Dis"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_913_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:34:18Z","timestamp":1787769258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_913_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_913_22","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"2022-11-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}